Numerous epidemiological studies have demonstrated an association between elevated C-reactive protein (CRP) levels and atherosclerotic cardiovascular (CV) disease (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) .
Despite persuasive epidemiological data, the majority of studies relating CRP to CV disease have been composed of patients who are less obese than the current U.S. population, where now more than two-thirds of adults are overweight or obese (12) . Because multiple epidemiological studies have also demonstrated a robust association between CRP and measures of obesity, it is plausible that the differing metabolic profile seen in obese compared with nonobese subjects may influence the relationship between CRP and CV disease.
CRP is predominantly produced in the liver in response to interleukin (IL)-6, which is one of several cytokines released by activated leukocytes and smooth muscle cells in atherosclerotic plaques (13) (14) (15) . However, adipose tissue is also a significant source of IL-6, which partially explains the strong correlation between obesity and CRP (16, 17) . Thus, the predictive value of CRP for CV disease may be diminished in obese individuals, in whom the CRP signal from adipose tissue may predominate over the signal from underlying atherosclerotic disease.
Given the uncertainty regarding the influence of obesity on the association between CRP and CV disease, we sought to determine whether the relationship between CRP and atherosclerosis differs by body mass index (BMI) category in a large, multiethnic, population-based cohort with a high prevalence of obesity and multiple measures of wellcharacterized atherosclerosis phenotypes.
Methods
Study population. The Dallas Heart Study (DHS) is a multiethnic, population-based probability sample of Dallas County adults. Details of the study design have been described (18) . The protocol was approved by the institutional review board of the University of Texas Southwestern Medical Center at Dallas, and all participants provided written informed consent to participate in the study.
In brief, from an initial cohort of 6,101 subjects who underwent a detailed in-home survey, 3,398 volunteered to provide blood and urine samples for laboratory testing, and 2,971 subsequently underwent a clinic visit with various imaging procedures, including coronary artery calcium (CAC) assessment and magnetic resonance imaging for aortic wall thickness (AWT) and aortic plaque burden (APB) measurements. The present study excluded those with BMI Ͻ18.5 (underweight) (n ϭ 9) and those with incomplete data to calculate the Framingham Risk Score (FRS) (n ϭ 63). Included in this cohort are those with CRP and BMI values, as well as a valid measure of CAC (n ϭ 2,685), AWT (n ϭ 2,238), or APB (n ϭ 2,224). High-sensitivity CRP. Blood samples were obtained after an overnight fast and stored for Յ4 h at 4°C in ethylenediaminetetraacetic tubes, and plasma aliquots were subsequently frozen at Ϫ80°C until biomarker assays were performed. High-sensitivity CRP measurements were carried out on thawed samples using the Roche/Hitachi 912 System, Tina-quant assay (Roche Diagnostics, Indianapolis, Indiana), a latex-enhanced immunoturbidimetric method (19) . The minimal detectable range of this assay is 0.1 mg/l, and the upper limit is 20 mg/l. Clinical validation of this assay has been described (2) . Coronary artery calcification. An Imatron C-150XP (Imatron Inc., San Francisco, California) electron-beam computed tomography scanner was used to measure CAC, with results expressed in Agatston units (20) . Duplicate scans were obtained 1 to 2 min apart, and the results were averaged. A score of Ͼ10 Agatston units was selected as a data-derived threshold to define the presence of CAC to maximize signal-to-noise ratio and reproducibility (21) . Aortic wall thickness and aortic plaque burden. A 1.5-T whole-body magnetic resonance imaging system (Intera, Philips Medical Systems, Best, the Netherlands) was used to obtain 6 transverse slices of the infrarenal abdominal aorta. Adventitial and luminal borders were outlined to determine total vessel area and luminal area, respectively. The AWT was calculated by subtracting the luminal radius from the total vessel radius, averaged over the 6 slices, as previously described (22) . Atherosclerotic plaque area was identified by hyperintense signal protrusions from the endoluminal surface (23) . The APB was calculated from the ratio of plaque area to total vessel area (24) . The sex-and agespecific (in 5-year increments) 75th percentile of AWT and APB were calculated using data from all subjects in the DHS cohort with such measurements. Study definitions. Hypertension was defined as one of the following: systolic blood pressure Ͼ140 mm Hg, diastolic blood pressure Ͼ90 mm Hg, or the use of antihypertensive medication. Hypercholesterolemia was defined as calculated low-density lipoprotein cholesterol (LDL-C) Ͼ160 mg/dl (4.1 mmol/l) on a fasting sample, direct LDL-C Ͼ160 mg/dl (4.1 mmol/l) on a nonfasting sample, total cholesterol Ͼ200 mg/dl (5.2 mmol/l), or use of statin medication. Low high-density lipoprotein cholesterol (HDL-C) was defined as HDL-C Ͻ40 mg/dl (1.04 mmol/l) in men and Ͻ50 mg/dl (1.29 mmol/l) in women. Diabetes mellitus was defined by one of the following: self-report accompanied by use of antihyperglycemic medication or by elevated serum glucose (fasting Ͼ126 mg/dl [7. 0 mmol/l] or by nonfasting glucose Ͼ200 mg/dl [11.1 mmol/l]). Family history of myocardial infarction was defined as a first-degree male relative who had a myocardial infarction at age Ͻ50 years or a female relative at age Ͻ55 years in survey responses. Race and ethnicity were defined by subject self-report. Smoking was defined as cigarette use within the previous 30 days and a lifetime history of having smoked Ͼ100 cigarettes. BMI was calculated on the basis of measured height and weight at study entry and categorized as normal weight (18.5 to Ͻ25 kg/m 2 ), overweight (25 to Ͻ30 kg/m 2 ), and obese (Ն30 kg/m 2 ) (25). The FRS for men and women was determined from major risk factors (including age, smoking, total cholesterol, HDL-C, and hypertension) according to the algorithm presented in the National Cholesterol Education Program (NCEP)-Adult Treatment Panel Three guidelines (26) . Metabolic syndrome was defined as having 3 or more of 5 standard criteria delineated by the NCEP (26) . Subjects with self-reported myocardial infarction or stroke were categorized in the high-risk category (i.e., FRS Ͼ20% 10-year risk of coronary heart disease) (26) . , and obese (Ͼ30 kg/m 2 ) (25). All analyses were stratified by BMI group. Given the previously published differing CRP distributions between men and women in the present cohort (19) , all analyses were sex stratified. Baseline demographic variables and CV risk factors were compared across BMI groups with chi-square trend test for categoric variables and with the test for trend across ordered groups for continuous variables. Subjects were categorized according to CRP cutpoints based on clinically recommended values (Ͻ1 mg/l, 1 to 3 mg/l, and Ͼ3 mg/l) (27) , sex-specific tertiles within the study cohort, and sex-and BMI-specific tertiles within the study cohort. Associations between CRP category and Baseline Characteristics in Women 
Values are mean Ϯ SD or median (interquartile range). BMI ϭ body mass index; CRP ϭ C-reactive protein; FRS ϭ Framingham Risk Score; HDL ϭ high-density lipoprotein; MI ϭ myocardial infarction; n/a ϭ not applicable. prevalent CAC were assessed using chi-square trend test. Odds ratios for prevalent CAC were calculated for CRP Ͼ3 versus Յ3 mg/l and for FRS Ͼ20% versus Յ20% 10-year risk. Interaction testing for obesity ϫ CRP on prevalent CAC was performed in sex-specific logistic models with terms for obesity (BMI Ͼ30 vs. Յ30 kg/m 2 ), categoric CRP (Ͼ3 vs. Յ3 mg/l), and their interaction. The correlations between CRP and FRS with AWT and APB were assessed using Spearman rank correlation coefficients. Interaction tests for these continuous outcomes were assessed in sexspecific linear regression models with similar obesity and CRP interaction terms. The ability of CRP to discriminate between those with and without CAC Ͼ10, AWT Ͼ75th percentile, and APB Ͼ75th percentile was assessed by calculating the c-statistic from logistic regression models. All statistical analyses were performed using SAS Version 9.2 (SAS Institute Inc., Cary, North Carolina).
Baseline Characteristics in Men

Results
The baseline characteristics of the study cohort stratified by sex are summarized in Tables 1 and 2 . The overall prevalence of overweight and obesity was 27% and 53% in women, respectively, and 38% and 38% in men, respectively. In both men and women, most CV risk factors were more prevalent in individuals with higher BMI. Median CRP levels also increased across BMI categories in both sexes, with larger increases among women as previously reported (28) .
The prevalence of CAC according to CRP levels in normal weight, overweight, and obese individuals stratified by sex is shown in Figures 1 to 3 . As CRP increased from Ͻ1 mg/l, to 1 to 3 mg/l, to Ͼ3 mg/l, the prevalence of CAC increased in normal weight women and in normal and overweight men (p trend Ͻ 0.01). However, in overweight and obese women, and in obese men, the prevalence of CAC was not significantly different across CRP categories (Figs. 1A  and 1B) .
Sex-specific tertiles of CRP for this population were Ͻ2.3 mg/l, 2.3 to 6.6 mg/l, and Ͼ6.6 mg/l in women, and Ͻ1.3 mg/l, 1.3 to 3.1 mg/l, and Ͼ3.1 mg/l in men. Using these thresholds resulted in no change in the relationship between CRP and CAC, with significant associations only in normal weight women and normal and overweight men ( Figs. 2A  and 2B ). When sex-and BMI-specific tertiles of CRP were evaluated, higher CRP levels did track with an increased prevalence of CAC among obese women, but not among obese men (Figs. 3A and 3B) . However, the highest CRP tertile in obese women involved a markedly high threshold of CRP (Ͼ9.9 mg/l). By using waist circumference categories instead of BMI, similar trends were seen with CRP having no statistical association with CAC among those with increased waist circumference ( Table 3) .
The odds ratio for CAC comparing CRP Ͼ3 mg/l versus Յ3 mg/l was also only significant in normal weight women and normal and overweight men, but not in the obese group for either sex (Table 4 ) (p interaction obesity ϫ CRP ϭ not significant in women, 0.04 in men). In contrast, a high FRS (Ͼ20% 10-year risk) was strongly associated with prevalent CAC in all BMI categories of both sexes.
The correlations between CRP and AWT and APB diminished with increasing BMI category, with no significant correlations among obese participants, whereas FRS remained correlated with these aortic atherosclerosis measures across all BMI groups (p Ͻ 0.001) ( Table 5 ). Interaction tests for obesity ϫ CRP were significant for both women and men for AWT (p interaction ϭ 0.01 and 0.002, respectively) and APB (p interaction ϭ 0.005 and 0.04, respectively).
In stratified analyses including the presence or absence of metabolic syndrome and BMI categories, CRP correlated with both AWT and ABP in normal weight women with or without the metabolic syndrome but was not associated with either measure among obese women regardless of metabolic syndrome status (Online Table 1 ). In men without the metabolic syndrome, CRP correlated with both AWT and ABP in normal and overweight subjects, but not in the obese. However, there was no statistical correlation between CRP and these aortic parameters in any BMI category among men with metabolic syndrome, although there were few normal weight men with this condition (n ϭ 28). The ability of CRP to discriminate between the presence or absence of CAC, AWT, and ABP, as measured by c-statistics, is shown for each BMI category in Table 6 . In both women and men, normal weight individuals tended to have higher c-statistics than obese individuals for all 3 atherosclerosis measures.
Discussion
In this large, multiethnic, population-based cohort, obesity modified the associations between CRP and multiple measures of atherosclerosis, such that the associations of CRP with atherosclerosis observed in normal weight individuals were diminished and nonsignificant among obese subjects. In contrast, the associations between the FRS and the atherosclerosis measures were significant across all BMI categories. These findings raise important Prevalence of Coronary Artery Calcium by CRP Cutpoints Among Waist Circumference Categories questions regarding the interpretation of CRP in obese individuals.
Despite the rapid increase in the prevalence of obesity, few data are available regarding the utility of current CV risk prediction tools in obese subjects. Previous studies linking CRP levels to CV outcomes were largely performed in populations with a lower prevalence of obesity than that of the current U.S. population (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) , where more than one-third of adults are now obese (12) . For example, in the 2 largest published studies of CRP and CV disease (2,11), the mean BMI of participants ranged from 25 to 26 kg/m 2 , lower than the recent reported mean of 28.7 kg/m 2 in U.S. adults (29) . In contrast, the Strong Heart Study examined the relationship between CRP and CV disease in a population with a high prevalence of obesity (mean BMI Ͼ30 kg/m 2 ) (30). After multivariable adjustment for demographic variables and traditional risk factors, no significant association was observed between elevated CRP levels (Ͼ3 mg/l) and CV events. However, subgroup analyses examining these relationships in obese compared with nonobese subjects were not performed (30) . Likewise, in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) cohort of Ͼ27,000 individuals, CRP levels Ͼ3 mg/l were most informative for all-cause mortality in underweight and normal-weight individuals, rather than the severely obese (p interaction ϭ 0.01, white subjects) (31) .
The predictive accuracy of CRP in obese subjects may be affected by the close correlation between CRP and adiposity. IL-6 is the principle cytokine that stimulates CRP release from the liver, and up to one-third of circulating IL-6 is released from adipose tissue (16, 17) . Furthermore, CRP is more closely correlated with measures of body composition than with any traditional CV risk factors (19) . For example, approximately 15% of the variance in CRP is determined by BMI compared with less than 3% due to LDL cholesterol (32, 33) . Therefore, the increase in CRP levels seen with obesity may lead to an overestimation of CV risk among obese subjects. In fact, it has been hypothesized that despite heightened inflammation in severely obese individuals, they may actually be protected from vascular dysfunction and atherosclerosis. One study demonstrated heightened mobilization of endothelial progenitor cells in morbidly obese versus obese subjects (34), whereas another study reported reduced expansion of CD4 ϩ
CD28
null T cells, directly cytotoxic lymphocytes that possess proatherosclerotic properties, in the morbidly obese (35) . In addition, the increased risk factor burden seen in obese individuals may offer competing risk and blunt the CV risk signal of CRP in these individuals, particularly because CRP only modestly correlates with these risk factors (32, 33) . Rho ϭ correlation coefficient; other abbreviations as in Table 4 .
Among overweight individuals in this study, the association between CRP and CAC differed between women and men, with positive associations only in overweight men. One possible explanation for this finding is that CRP levels increase to a greater degree with increased adiposity in women compared with men (19, 28) . Alternatively, overweight women may have a greater quantity of body fat compared with overweight men, despite being in the same BMI category (36) .
BMI is a crude measure of total body adiposity, and central adiposity as measured by waist circumference may be a superior marker of metabolic risk. By using NCEPdefined waist circumference cutpoints rather than BMI categories, we observed similar results with increasing CAC prevalence with higher CRP levels among those with normal waist circumference, but not among those with increased waist circumference. In addition, in the Women's Health Study, CRP was only informative for CV events among those with the metabolic syndrome, and not all obese individuals meet criteria for this entity (37) . Nevertheless, we did not observe any association between CRP and atherosclerosis among obese subjects with or without the metabolic syndrome.
Consistent with our previous report (38) , CRP is generally a poor predictor of subclinical atherosclerosis with an overall c-statistic of 0.56 for the discrimination of detectable CAC. However, we observed a trend toward decreasing c-statistic values for obese compared with normal weight subjects, such that the statistically significant associations between CRP and multiple atherosclerosis measures found in normal weight subjects were not evident in obese subjects. It is plausible that higher CRP thresholds may be required in obese populations to reveal associations with CV disease. For example, the Strong Heart Study investigators demonstrated that using an upper CRP threshold of 4 mg/l, as opposed to 3 mg/l, resulted in higher CV risk estimates, which remained significant after multivariable adjustment (30) . Current Centers for Disease Control and Prevention/ American Heart Association recommendations of using a threshold of 3 mg/l to denote high relative risk are based on the tertiles of CRP distribution from selected cohorts with a lower prevalence of obesity than that in the U.S. population and the DHS (27) . Adjusting CRP cutpoints based on sex-specific tertiles within the study cohort did not strengthen the association between CRP levels and CAC in obese individuals, but using sex-and BMI-specific cutpoints did result in a statistically significant association between CRP and CAC in obese women. However, the cutpoint required to detect this relationship involved a markedly high threshold of CRP (Ͼ9.9 mg/l) that requires exploration and confirmation in other cohorts and with clinical events.
Despite the large sample size, ethnic diversity, and high prevalence of obesity of this population-based cohort, several potential limitations merit comment. First, the reduced accuracy of CRP as a marker of prevalent atherosclerosis in obese subjects could represent imprecision of these atherosclerosis measurements in obese individuals and lead to misclassification bias. However, using a threshold of 10 Agatston units for detectable CAC has been shown to have Ͼ90% interscan concordance in those with BMI Ͼ30 kg/m 2 (21) . In addition, when using FRS as a control, we observed little change in the strong relationship between FRS and CAC, AWT, and APB with increasing BMI. Also, the interaction testing for CRP and obesity on prevalent CAC was not significant among women. However, the interaction tests were significant in women for both AWT and ABP and across all atherosclerosis phenotypes in men, and the low prevalence of CAC in women reduced the power to detect a significant interaction in this group. Finally, our findings regarding the effects of obesity on the relationship between CRP and radiographic measures of atherosclerosis cannot be directly extrapolated to clinical CV events. CRP may be more reflective of rupture-prone, unstable coronary plaques than the burden of atherosclerotic disease (39) . Further studies with clinical endpoints are needed to explore the utility of CRP testing in obese subjects, including an assessment of optimal risk cutpoints.
Conclusions
In a large, multiethnic, population-based study, obesity modifies the association between CRP and atherosclerosis, such that the association between CRP and multiple atherosclerosis phenotypes is diminished in obese individuals of both sexes. Because CRP may be a better marker of plaque instability than plaque presence, additional studies with clinical events are needed to clarify the relationship between CRP and CV outcomes in obese individuals.
